grant
Novel MUC1 Theranostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer
Organization STANFORD UNIVERSITYLocation STANFORD, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2026AffinityAntibodiesBase SequenceBenchmarkingBest Practice AnalysisBindingBiodistributionBiologicalBiologyBlood SerumBreast CancerBreast Cancer CellBreast Cancer PatientBreast Tumor PatientCancer CauseCancer EtiologyCancersCell BodyCellsCessation of lifeChelating AgentsChelatorsClinicalComplexComplexonsCyclizationDeathDevelopmentDiagnosisDiagnostic ImagingDiseaseDisorderDoseDrug KineticsERBB2ERBB2 geneEstrogen ReceptorsExhibitsExternal DomainExtracellular DomainFOLHFOLH1FOLH1 geneFolate Hydrolase 1FoundationsFutureGCP2Ga elementGalliumGlutamate Carboxypeptidase IIGoalsHER -2HER-2HER2HER2 GenesHER2/neuHematologyImageKnowledgeLabelLibrariesLutetiumMUC-1MUC1MUC1 gene productMalignant Breast NeoplasmMalignant CellMalignant NeoplasmsMalignant TumorMasksMetabolic GlycosylationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMetastatic breast cancerMindMinisatellite RepeatsMinisatellitesModelingModificationMolecularMolecular InteractionMorbidityMuc1 MucinMucin 1Mucin 1 proteinN-Acetylated Alpha-Linked Acidic Dipeptidase 1NAALAD1NAALADase INEU OncogeneNEU proteinNeoplasm MetastasisNormal CellNormal TissueNormal tissue morphologyNucleotide SequenceOncogene ErbB2OrganPETPET ScanPET imagingPETSCANPETTPSMPSMAPatientsPatternPeptidesPharmacokineticsPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyProductionProgesterone ReceptorsProgestin ReceptorsPrognosisPropertyProstate-Specific Membrane AntigenProteinsRad.-PETRadiation DoseRadiation Dose UnitRadioactive IsotopesRadioisotopesRadiolabeledRadionuclide therapyRadionuclidesRandomized Controlled Clinical TrialsReceptor ProteinSPECTSPECT imagingSRIH ReceptorsSYS-TXSecondary NeoplasmSecondary TumorSerumShort interfering RNASimple Repetitive SequenceSingle-Photon Emission-Computed Radionuclide TomographySmall Interfering RNASomatostatin ReceptorSomatotropin Release Inhibiting Hormone ReceptorsSpecificitySpinal ColumnSpineSurface Plasmon ResonanceSystemic TherapyTKR1TNBCTandem Repeat SequencesTandem RepeatsTechniquesTestingTherapeutic StudiesTherapy ResearchToxic effectToxicitiesTumor CellVNTRVNTR LociVNTR RegionVNTR SequencesValidationVariable Number of Tandem RepeatsVariable Tandem RepeatsVertebral columnWomanbackbonebenchmarkbiologicbreast tumor cellc-erbB-2c-erbB-2 Genesc-erbB-2 Proto-Oncogenescancer cellcancer diagnosiscancer metastasischemotherapyclinical relevanceclinical translationclinically relevantclinically translatablecomparativecostcytotoxiccytotoxic radiationdensitydesigndesigningdevelopmentaldisease controldisorder controlerbB-2 Genesestrogen receptor proteinestrophileestrophilinexpression subtypesglycosylationherstatinimagingimaging approachimaging based approachimmunogenicityimprovedin vivoindividuals with breast cancerknock-downknockdownmalignancymalignant breast tumormetal chelatormetastatic breast tumormetastatic mammary cancermetastatic mammary tumormolecular sub-typesmolecular subsetsmolecular subtypesmolecular targeted therapeuticsmolecular targeted therapiesmolecular targeted treatmentmortalitymouse modelmurine modelneoplasm/cancerneoplastic cellneu Genesnovelnucleic acid sequenceoptimal therapiesoptimal treatmentsoverexpressoverexpressionpatients with breast cancerpeptide aminoacid sequencepeptide sequenceperson with breast cancerpositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographyprotein aminoacid sequenceradiolabelradiolabelingradiolabelsradiologically labeledradiotracerrandomized control clinical trialreceptorreceptor bindingreceptor boundreceptor densityreceptor internalizationsafety assessmentsiRNAside effectsingle photon emission computed tomographysubcutaneoussubdermaltargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttheranosticstherapeutic radionuclidetherapeutic targettriple-negative breast cancertriple-negative invasive breast carcinomatumortumor cell metastasisuptakevalidationsvector
Description preview
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer defined by a poor overall prognosis, aggressive and early pattern of metastases, and a lack of treatments that lead to sustained disease control. There is a critical need for molecular targeted treatments for patients with TNBC that are more effective, have reduced side…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click